PBYI Puma Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PBYI

Price (delayed)

$7.015

Market cap

$357.06M

P/E Ratio

14.03

Dividend/share

N/A

EPS

$0.5

Enterprise value

$334.73M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 77
Relative Profitability: Rel. Profitability: 80

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights
Puma Biotechnology's debt has shrunk by 74% YoY and by 44% QoQ
Puma Biotechnology's quick ratio has soared by 59% YoY and by 15% from the previous quarter
The P/E is 66% higher than the last 4 quarters average of 8.2
The net income has contracted by 36% YoY and by 22% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pumabiotechnology.com
Peers: ARRY PFE

Key stats

What are the main financial stats of PBYI

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
3.01%
1 week
-3.11%
1 month
-6.84%
1 year
97.05%
YTD
17.9%
QTD
9.78%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$227.18M
Gross profit
$169.15M
Operating income
$29.49M
Net income
$24.38M
Gross margin
74.5%
Net margin
10.7%
The net income has contracted by 36% YoY and by 22% from the previous quarter
Puma Biotechnology's net margin has decreased by 35% YoY and by 21% QoQ
The operating income has contracted by 21% from the previous quarter and by 21% YoY
The operating margin has contracted by 20% from the previous quarter and by 19% YoY

Price vs fundamentals

How does PBYI's price correlate with its fundamentals

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
PBYI P/E details
P/E
14.03
P/B
2.78
P/S
1.57
EV/EBIT
9.77
EV/EBITDA
7.44
EV/Sales
1.47
The P/E is 66% higher than the last 4 quarters average of 8.2
PBYI's EPS is down by 35% year-on-year and by 19% since the previous quarter
PBYI's P/B is 46% lower than its 5-year quarterly average of 5.0 but 23% higher than its last 4 quarters average of 2.2
Puma Biotechnology's equity has increased by 32% YoY
PBYI's P/S is 90% above its 5-year quarterly average of 0.8 and 27% above its last 4 quarters average of 1.2
The revenue has contracted by 2.4% YoY

Efficiency

How efficient is Puma Biotechnology business performance
Puma Biotechnology's ROE has plunged by 59% YoY and by 27% from the previous quarter
The ROA has decreased by 34% YoY and by 21% QoQ
PBYI's ROIC is down by 23% QoQ and by 22% YoY
PBYI's return on sales is down by 19% since the previous quarter and by 19% year-on-year

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The total assets is 200% more than the total liabilities
Puma Biotechnology's quick ratio has soared by 59% YoY and by 15% from the previous quarter
The company's current ratio has surged by 56% YoY and by 19% QoQ
Puma Biotechnology's debt is 88% lower than its equity
Puma Biotechnology's debt to equity has shrunk by 81% YoY and by 45% QoQ
Puma Biotechnology's debt has shrunk by 74% YoY and by 44% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.